Instead, Grade 2 meningiomas showed an allocation to the MCs ‘benign’ (approximately two‐thirds), ‘intermediate’ (just over one‐third), ‘malignant’ (3%) and SMARCE1‐altered (1.6%) (Figure 3 and Table S3). The gene discussed is SMARCE1; the disease is meningioma.